India's Sun Pharmaceutical has signed a longterm agreement with South Korean CMO Samsung BioLogics for the manufacture of an experimental psoriasis treatment.
The novel investigational biologic, known as tildrakizumab, is currently under review by the US FDA and the European Medicines Agency (EMA).
Sun Pharma's subsidiary received worldwide rights to tildrakizumab from Merck (through a Merck subsidiary), known as MSD outside the United States and Canada, in 2014.
Read the press release
